bioAffinity Technologies (BIAF) Total Liabilities (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Total Liabilities for 6 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 4.28% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 4.28% YoY), while the FY2025 annual figure was $3.7 million, down 5.84% from the prior year.
• Total Liabilities advanced to $4.3 million in Q1 2026 per BIAF's latest filing, from $3.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $6.9 million in Q2 2025 and bottomed at $775151.0 in Q2 2023.
• Historically, Total Liabilities has averaged $3.0 million across 5 years, with a median of $3.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities slumped 91.37% — and 2024, when it jumped 315.83%.
• bioAffinity Technologies' Total Liabilities stood at $1.1 million in 2022, then soared by 195.63% to $3.4 million in 2023, then advanced by 16.2% to $3.9 million in 2024, then retreated by 5.84% to $3.7 million in 2025, then increased by 16.31% to $4.3 million in 2026.
• Business Quant data shows BIAF's Total Liabilities at $4.3 million in Q1 2026, $3.7 million in Q4 2025, and $2.6 million in Q3 2025.